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Assessment of the endometrium often necessitates a biopsy, which currently involves an
invasive, transcervical procedure. Here, we present an alternative technique based on
deriving organoids from menstrual flow. We demonstrate that organoids can be derived from
gland fragments recovered from menstrual flow. To confirm they faithfully reflect the in vivo
state we compared organoids derived from paired scratch biopsies and ensuing menstrual
flow from patients undergoing in vitro fertilisation (IVF). We demonstrate that the two sets of
organoids share the same transcriptome signature, derivation efficiency and proliferation
rate. Furthermore, they respond similarly to sex steroids and early-pregnancy hormones, with
changes in morphology, receptor expression, and production of ‘uterine milk’ proteins that
mimic those during the late-secretory phase and early pregnancy. This technique has wide-
ranging impact for non-invasive investigation and personalised approaches to treatment of
common gynaecological conditions, such as endometriosis, and reproductive disorders,
including failed implantation after IVF and recurrent miscarriage.
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Organoids are self-organising, three-dimensional culturesystems that can be cultured long-term and faithfullyreflect the structure and function of their tissue of origin.
They have now been derived from many tissues, and have proved
powerful tools for the investigation of normal development and
modelling disease1. Their physiological responsiveness enables
them to be used to predict drug effects, and they open new
avenues for personalised regenerative medicine.
We, and others, have previously shown that endometrial
organoids provide a valuable model for investigating maternal-
fetal interactions during early pregnancy, and for exploring the
pathophysiology of gynaecological complications such as endo-
metriosis and endometrial cancer2–5. To date, the organoids have
been derived from biopsy samples, which, while reproducible and
robust, necessitate an invasive procedure performed by a trained
clinician. We therefore determined whether organoids can be
derived non-invasively from menstrual flow. To assess whether
these faithfully replicate the molecular signature of the endome-
trium in vivo, we adopted a unique experimental approach
whereby women undergoing an endometrial scratch as part of an
in vitro fertilisation (IVF) procedure were invited to collect
menstrual flow from the same cycle using an endometrial cup.
Results
Optimisation of the protocol. We performed an initial pilot
study to optimise the technique for derivation of organoids from
menstrual flow. We received samples of flow collected in a
menstrual cup from seven volunteers with normal cycles, and
succeeded in deriving organoids from six. A repeat sample from
the volunteer whose culture was unsuccessful also failed. Cells
isolated from the flow appeared dead, and we attributed this to
sample collection/volunteer problems and did not explore the
issue further. A further three volunteers provided repeat samples,
and we successfully derived organoids from all. The detailed
protocol is given in the Methods, and was followed for the
derivation of organoids from clinical samples.
Growth characteristics of organoids derived from menstrual
flow. In order to validate the menstrual flow organoids, we
derived organoids from endometrial scratches and ensuing
menstrual flow of volunteers undergoing an IVF treatment cycle
at the Bourn Hall Clinic (Fig. 1a). We received menstrual samples
from eight patients and succeeded in deriving organoids from
seven. In the failed sample, the starting tissue appeared white and
dead, but the cause was not explored further. Altogether, the
success rate of deriving organoids from menstrual flow was 87%.
The rate of growth varied between patients, as it does in
organoids derived from pipelle biopsies3 (Fig. 1b–d and
Supplementary Fig. 1). We were also able to freeze menstrual
gland digest samples and recover them later (Fig. 1b and
Supplementary Fig. 1). Organoids obtained from menstrual blood
vs. scratch biopsies were indistinguishable morphologically
(Fig. 1e). In most cases, the initial yield of tissue fragments from
menstrual flow was lower than that obtained from scratch
biopsies. However, the speed of organoid establishment was
comparable to that from endometrial pipelle biopsies3. To
compare the growth rate of menstrual vs. scratch organoids, we
quantified organoid efficiency formation in paired single-cell
Fig. 1 Derivation and characterisation of menstrual flow organoids. a Schematic to illustrate how organoids were derived from an endometrial scratch
and menstrual flow in the same cycle. b–d Time line images detailing propagation of organoids from menstrual flow and scratch. b The panel represents the
growth of menstrual organoids directly derived from menstrual blood. c, d The panels illustrate the growth of organoids from frozen menstrual (c) and
scratch (d) digests of the same patient. Scale bar 400 μm. e Organoids derived from an endometrial scratch and menstrual flow of the same patient are
indistinguishable morphologically. Scale bar 200 μm. f, g Single-cell assay to compare the growth of paired menstrual vs. scratch organoids derived from
four patients. Images show organoids seeded from single cells (5000 cells per 20 μl drop Matrigel) after 9 days of growth (f). Quantification of the single-
cell assay. Scale bar 2000 μm. Five to 8-well repeats were quantified per condition (g). h Representative images of immunostaining against the marker of
proliferation, Ki67, in menstrual and scratch organoids of one patient. Scale bar 50 μm. i Quantification of the Ki67 proliferation index in menstrual vs.
scratch organoids of three patients.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02194-y
2 COMMUNICATIONS BIOLOGY |           (2021) 4:651 | https://doi.org/10.1038/s42003-021-02194-y | www.nature.com/commsbio
assays and observed no difference (mean ± SE organoid efficiency
formation: 62.67 ± 19.70 menstrual organoids vs. 57.97 ±
16.64 scratch organoids formed after 9 days from 5000 single
cells seeded per well, p= 0.86) (Fig. 1f, g). We also assessed
organoid proliferation rate using Ki67 staining (Fig. 1h, i), and
again found no difference (mean ± SE Ki67 proliferation rate:
27.76 ± 4.32% menstrual vs. 28.12 ± 4.16% scratch; p= 0.95).
Menstrual flow organoids began to form after 2–4 days in culture
if grown from fresh samples (Fig. 1b), or after 5 days if grown
from frozen digests (Fig. 1c, d and Supplementary Fig. 1), and
were ready to passage after 7–10 days (Fig. 1b, d and
Supplementary Fig. 1).
Characterisation of organoids derived from menstrual flow.
RNA sequencing (RNA-Seq) revealed that organoids derived
from scratch biopsies and menstrual flows clustered together
(Fig. 2a). In addition, each patient’s organoids paired up, showing
conservation of transcripts across the two sources (Fig. 2b). The
menstrual flow organoids expressed a transcript signature rich in
markers of progenitor cells (LRIG1, PROM1, AXIN2, SOX9),
proliferation (MKI67, PCNA, TOP2A), epithelial cell lineage
(EPCAM, KRT7, CLDN10, CDH1), endometrial gland develop-
ment and function (FOXA2, KLF5, SOX17), epithelial secretory
activity (PAEP, MUC1, MUC20, PAX8, KLK11, SPP1), receptors
to pregnancy hormones (PGR, PRLR, PRLHR, GHR, ESRRA,
ESRRB, ESRRG, ESR2), and cilia formation (FOXJ1, PIFO,
RSPH1), in an identical pattern to organoids derived from the
scratch biopsies (Fig. 2c).
To validate the physiological relevance of the menstrual flow
organoids, we tested their responsiveness to treatment with early-
pregnancy hormones and found they reacted in an identical
fashion to those derived from scratch biopsies from the same
patient. Treatment with progesterone, oestrogen, cAMP, as well
as prolactin (PRL), human placental lactogen (hPL) and human
chorionic gonadotropin (hCG) increased the mRNAs encoding
PAEP (glycodelin, GdA), MUC1, and LIF (Fig. 2d), as well as
PAEP/glycodelin, and MUC1 protein expression (Fig. 2e, f), and
increased secretion of glycodelin in culture supernatants (Fig. 2g)
of both menstrual and scratch organoids.
Response of organoids to sex steroids and early-pregnancy
hormones. Administration of progesterone, oestrogen, cAMP,
PRL, hPL and hCG also increased expression of acetylated
tubulin, P4-R, and PRL-R (Fig. 3a). We explored the changes in
P4-R further. Combined hormonal treatment induced an increase
in P4-R expression in menstrual and scratch organoids when
compared to the control medium culture, in agreement with
previous reports3 (Fig. 3a–c). However, treatment with E2 alone
induced an extensive increase in P4-R expression, which was
suppressed when P4 was added to the culture medium of both
menstrual and scratch organoids (Fig. 3d). These results are in
line with reports of increased progesterone receptor during the
proliferative phase of the cycle (E2 dominant), and its down-
regulation during the secretory phase and early pregnancy (P4
dominant)6.
Fig. 2 Comparative characterisation of menstrual and scratch organoids and their response to hormones. a PCA plot shows top 2000 variable genes
clustering of organoids derived from scratch biopsies and menstrual flow of seven patients analysed by RNA-Seq. b A heatmap of scratch and menstrual
organoids demonstrates pairing of organoids in each of seven patients using the 101 differential expressed genes with threshold padj < 0.05, abs(log2Fold-
Change) >= 1. c A heatmap validating expression of epithelial, secretory and stem cell markers in scratch and menstrual organoids. d, g Menstrual flow
organoids are hormonally responsive. Organoids were grown for 4 days, and treated with culture medium alone or β-estradiol for 2 days followed by β-
estradiol, progesterone and cAMP (EPC), EPC plus prolactin, or EPC plus prolactin, hPL and hCG for 4 days. d mRNA of PAEP, LIF and MUC1 was quantified
using qRT-PCR in hormonally treated menstrual organoids (n= 3). Statistical significance was assessed using ANOVA, p-values are shown on each graph.
e, fMenstrual flow and scratch organoids (n= 5 each) responded similarly to hormones at the protein level. PAEP/glycodelin, MUC1 and LIF were detected
by western blotting. g Quantification of secreted glycodelin detected in the supernatants of menstrual and scratch organoids (n= 4 each) treated with
hormones. Statistical significance was assessed using ANOVA, p-values are shown on each graph, error bars represent standard deviation.
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In addition to inducing the formation of ciliated cells, as
marked by increased expression of acetylated tubulin (Fig. 3a),
application of steroid hormones alone, or in combination with
PRL, hPL and hCG, induced a columnar epithelial morphology
with increased vacuole formation analogous to the hypersecretory
phenotype of early pregnancy (Fig. 3e, f and Supplementary
Figs. 2 and 3)7. Increased staining of semi-thin resin sections with
the lectins Bandeiraea simplicifolia -II (BSA-II) (Fig. 3f) and
Arachis hypogaea agglutinin (AHA) was observed in both sets of
organoids following treatment with hormones, in agreement with
upregulation of glycoproteins in gland epithelial cells during the
mid-secretory phase of the cycle and early pregnancy8,9 (Fig. 3f
and Supplementary Fig. 3). In addition, there was evidence of
increased glycogen secretion by hormonally challenged menstrual
and scratch organoids, as detected by the BSA-II lectin (Fig. 3f,
BSA-II binds to amylase-sensitive glycogen) and by PAS staining
(Supplementary Fig. 4).
Discussion
Our results demonstrate that menstrual flow contains viable
endometrial gland progenitor cells, and can be used to derive
physiologically relevant organoid cultures in a non-invasive
manner. We confirmed that the transcriptome of the resultant
organoids is identical to that of organoids generated from an
endometrial biopsy taken earlier in the same cycle. Furthermore,
the two sets of organoids respond in the same fashion to steroid
and early-pregnancy hormones, upregulating expression and
secretion of ‘uterine milk’ proteins. Together, our findings vali-
date the use of menstrual flow as an easily obtainable and non-
invasive alternative to endometrial biopsies for the derivation of
endometrial organoids.
The human endometrium is a uniquely dynamic tissue con-
trolled by the hypothalamic-pituitary-gonadal axis, mediated by a
sequential interplay of sex hormones during the menstrual cycle.
Following menstruation, the oestrogen-dominated proliferative
phase promotes regrowth of the mucosa, which then differ-
entiates and increases in functional activity during the
progesterone-dominated secretory phase. Endometrial glands
open onto the surface epithelium of the uterus that comprises a
mix of ciliated and non-ciliated cuboidal cells. The glands are of
the simple tubular form, interconnected basally10, and are lined
by a columnar epithelium. In preparation for implantation, the
glands and intervening stromal cells undergo differentiation and
an increase in secretory activity. The hormonal microenviron-
ment coupled with secretions from the glands regulates the
receptivity of the endometrial epithelium and the implantation
competency of the blastocyst11,12. If pregnancy does not ensue,
shedding occurs at menstruation, with regeneration during the
proliferative phase of the next cycle. Our results demonstrate that
both the menstrual and scratch organoids undergo equivalent
changes in response to treatment with sex steroids.
A further increase in activity is seen during early pregnancy
when the glands adopt a hypersecretory phenotype, the Arias-
Stella reaction7, thought to be induced by hormones released from
the conceptus and decidua. In domestic species it is well
Fig. 3 Morphological changes in menstrual and scratch organoids in response to hormones. a Menstrual organoids show immunohistochemical
upregulation of PAEP/GdA, acetylated tubulin, progesterone receptor (P4-R) and prolactin receptor (PRL-R) in response to hormones as organoids derived
from pipelle biopsies. Scale bar 50 μm. b, c Treatment of menstrual and scratch organoids (n= 4 each) with different pregnancy hormones increased the
expression of the progesterone receptor (P4-R), as detected by western blotting (a) and quantified (b). Statistical significance was assessed using
ANOVA, p-values are shown on each graph, error bars represent standard deviation. d Representative western blots of menstrual and scratch organoids
treated with a range of pregnancy hormones, including oestrogen alone (E2), which induced major upregulation of the P4-R expression. Adding of P4 alone
or in combination with other hormones reduced E2-induced P4-R expression. e Representative images of haematoxylin and eosin (H&E) staining of
hormonally treated menstrual and scratch organoids from one patient, showing morphological differences between untreated vs. hormonally treated
organoids. Scale bar 25 μm. f Bandeiraea simplicifolia -II (BSA-II) lectin staining of semi-thin resin sections of menstrual and scratch organoids treated with
hormones. Scale bar 50 μm.
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established that the conceptus stimulates and regulates its early
development through a dialogue with the endometrial glands13–15.
In particular, increased stimulation by progesterone, prolactin,
and trophoblast-produced hormones leads to increased secretion
of ‘uterine milk’ proteins and growth factors (e.g., EGF, LIF),
which, in turn, stimulate trophoblast growth and differentiation.
These effects also involve changes in receptor expression on the
gland cells13–15. We speculate that a similar mechanism operates
in the human3,16 and the data presented here further support
the case.
The ‘uterine milk’ proteins provide essential histotrophic
nutrition for the conceptus during the first trimester of pregnancy
before the definitive haemochorial placenta is established17. The
importance of histotroph during early pregnancy has been
demonstrated in animal models. Suppression of gland develop-
ment in the sheep and mouse leads to failure of the conceptus to
thrive and implant18,19 As a corollary in the human, deficient
gland function may contribute to poor placental development and
early-pregnancy loss. For example, the composition of uterine
fluid during the secretory phase of the cycle is abnormal in
women with idiopathic infertility compared to fertile controls20.
Also, pilot studies indicate that levels of prolactin and the gly-
codelin A, one of the major components of histotroph, are
abnormally low in women suffering implantation failure or early-
pregnancy loss21,22. In the human, the prolactin that appears to
be a powerful stimulant of gland activity during early pregnancy
is secreted by the decidua rather than the trophoblast as in other
species23. This may explain the mounting evidence linking
defective decidualisation to miscarriage and other complications
of pregnancy24.
Investigating the physiology and function of the normal cycling
endometrium is challenging due to its great variability between
individuals25, reflecting the profound effects of diverse factors,
including BMI, age and parity. Exploring the impact of these
factors on implantation and early pregnancy is even more difficult
due to obvious ethical concerns and the lack of a suitable animal
model. Generating organoids non-invasively from a broad
population of women will provide essential data to fill these
important knowledge gaps. The organoids can be frozen, bio-
banked and thawed, allowing for future large-scale retrospective
studies. They can also be seeded on to three-dimensional collagen
scaffolds, paving the way for the development of co-culture
techniques with which to explore implantation26. Currently,
endometrial organoids are being used to investigate physiological
changes during the normal cycle5, and pathological endometrial
dysfunction in endometriosis, endometrial cancer and other
gynaecological conditions2. Implantation of the transferred
embryo is a rate-limiting step in Assisted Reproductive Techni-
ques (ART)27, and organoids are enabling exploration of the
molecular mechanisms underpinning implantation4. Our tech-
nique will enable patients undergoing fertility treatments to have
their endometrial function assessed non-invasively prior to
initiating a treatment cycle, allowing the hormonal regime and
timing of treatment to be tailored accordingly. This approach
provides opportunities for personalised medicine in a similar
fashion to that of kidney organoids derived from the urine of
patients28.
The derivation of endometrial organoids from menstrual fluid,
therefore, opens new avenues for assessing endometrial function
in health and disease, and hence we anticipate has widespread
applications in clinical practice.
Methods
Subjects
Pilot study. We recruited seven healthy volunteers for the pilot study with informed
written consent (ethical approval HBREC.2017.10). Volunteers had normal cycles,
and included nulliparous and parous individuals. Samples were collected on an
anonymised basis.
Bourn Hall Clinic patients. Seven patients who undertook an elective endometrial
scratch (ES) procedures prior to initiation of a treatment cycle at Bourn Hall Clinic,
Cambridge, agreed to collect a sample of the menstrual flow that subsequently
followed the ES procedure. Endometrial gland organoids were derived from a tissue
sample taken during the ES procedure, as well as from a sample of menstrual flow.
All procedures were carried out with informed written consent, and local ethics
approval (East of England—Cambridge Central Research Ethics Committee 17/EE/
0151). Patients’ clinical details are listed in Table 1.
Hormonal stimulation and IVF procedures. The endometrial scratch procedure
(ES) was performed during the luteal phase of the cycle immediately prior to the
treatment cycle. Six patients initiated scheduled treatments by inducing a with-
drawal bleed after the oral contraceptive pill; one patient started luteal phase
downregulation with a GnRH agonist the day after the ES procedure.
Stimulation for the treatment cycle was initiated within a few days after
menstruation; patients who were treated with an OCP/Antagonist regime started
gonadotropin stimulation on day 2 or 3. The patient who was treated with a luteal
phase downregulation protocol started stimulation 21 days following her menstrual
bleed. Blastocysts were transferred on day 5 after OCR. Two patients responded
poorly to stimulation, with only one (B75) or two (B55) oocytes fertilised; their
cleavage stage embryos were transferred on Day 2 after OCR. Two further patients
were treated with a hormone replacement regime for endometrial preparation prior
to scheduled transfer of blastocysts vitrified in a previous cycle; blastocysts were
warmed and transferred 5 days after presumed ovulation.
Table 1 Clinical details.
Sample ID Outcome Previous obstetric
history
BMI Age Treatment Drug protocol
B55 Not pregnant Para 0+ 0 30.48 39 ICSI; two cleavage stage embryos
transferred (2c, 4c) on Day 2
Antagonist+
gonadotrophin
B60 Elective CS @ 37 wks,
Twins (2900 g & 2300 g)




B61 Not pregnant Para 0+ 0 26.4 33 FET Single BT, Day 5 HRT
B70 Live Birth, 38+ 2 wks
(3657 g)
Para 0+ 2EPL 19.96 27 FET; two blastocysts transferred Day 5 HRT




B74 Unknown Para 1+ 1EPL Not
recorded
49 For IVF Rx in Cyprus unknown




EPL Early-pregnancy loss, FET frozen embryo transfer, BT blastocyst transfer.
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Extraction of endometrial gland organoids from menstrual flow. Patients were
supplied with a reusable menstrual cup (Mooncup, type A or B depending on their
age and/or obstetric history) and its proper use was explained. Patients were
instructed to collect menstrual flow in a sterile 50-ml tube as soon as the flow
became heavy on day 1–2. This was to be achieved by collecting the heavy flow
sample during the day over at least 4 h (minimum ~ 7ml blood), or overnight, and
the sample was kept refrigerated. Menstrual samples were couriered to the lab and
either processed immediately, or kept at 4 °C and processed the next day. Samples
were spun down at 600 × g for 5 min and washed with phosphate buffered saline
(PBS) several times to remove red blood cells, discarding the bloody supernatant
and collecting only the cellular material after every wash. The cellular sediment was
subsequently passed through a 100-μm sieve (Corning, 431752) and washed with
more PBS. The sieve was inverted over a Petri dish and retained cellular debris was
backwashed from the sieve membranes, to collect the solid endometrial gland-
containing material. Collected tissue debris was chopped with a scalpel into small 5
mm fragments and then digested in 20 ml 25 U/ml Dispase II (Sigma, D4693)/0.4
mg/ml collagenase V (Sigma, C-9263) solution in RPMI 1640 medium (Thermo
Fisher Scientific, 21875-034)/10% FBS) with gentle shaking at 37 °C for 20 min.
The solution was then neutralised with 20 ml cold RPMI 1640/10% FBS medium
and passed through a clean 100-μm sieve. The sieve was inverted again over a Petri
dish and retained glandular elements were backwashed from sieve membranes,
using vigorous bursts of medium from a disposable Pasteur pipette, pelleted by
centrifugation and resuspended in ice-cold Matrigel (Corning, 536231) at a
volume: volume ratio of 1:20. Twenty-five microlitre drops of Matrigel–cell sus-
pension were plated into 48-well plates (Costar, 3548), allowed to set at 37 °C and
overlaid with 250 μl organoid culture medium, as described previously3. See Sup-
plementary Fig. 5 for more details. The medium was changed every 2–3 days and
cultures were passaged by manual pipetting every 7–10 days.
Derivation of endometrial organoids from endometrial scratch biopsies.
Endometrial gland organoids were derived from scratch biopsies, as previously
described3. Briefly, endometrial scratch biopsies were dissected using scalpels into
~0.5 mm3 cubes and enzymatically digested in 20 ml solution of 1.25 U/ml dispase
II (Sigma, D4693)/0.4 mg/ml collagenase V (Sigma, C-9263) in PRMI 1640 med-
ium containing 10% FBS with gentle shaking at 37 °C for 20–30 min. The super-
natant was neutralised with medium and passed through one or more 100 μm cell
sieves (Corning, 431752) and the sieve washed several times with medium. The
sieves were inverted over a Petri dish and retained glandular elements were
backwashed from the sieve membranes, pelleted by centrifugation and resuspended
in ice-cold Matrigel (Corning, 536231) at a ratio of 1:20 (vol:vol). Twenty-five
microlitre drops of Matrigel–cell suspension were plated into 48-well plates
(Costar, 3548), allowed to set at 37 °C and overlaid with 250 μl organoid Expansion
Medium (ExM)3. The medium was changed every 2–3 days. Cultures were pas-
saged by manual pipetting every 7–10 days.
Freezing and recovery of menstrual and scratch organoids. Menstrual and
scratch organoids were frozen in the freezing medium containing 70% organoid
culture medium, 20% FBS and 10% DMSO. All derived organoids, as well as the
starting digests, were frozen and biobanked, starting from gland/menstrual digests
(passage 0) to higher passages. The viability of the frozen cultures reflects that of
the cultures before freezing. For all experiments presented in this paper, we thawed
established organoid cultures (not frozen digests) of a low passage (1–3), expanded
their numbers and used experimentally. The derivation of organoids from frozen
menstrual and gland digests was only presented (Fig. 1c, d and Supplementary
Fig. 1) to show this as an alternative to deriving organoids from fresh digests, and
to demonstrate for one patient the ease and comparability of deriving organoids
from menstrual blood vs. endometrial scratch.
Organoid treatment and processing. For the hormonal challenge, organoids were
seeded and grown for 4 days, followed by treatment with culture medium alone, or
with hormones, which consisted of pre-treatment with β-estradiol (10 nM) for
2 days, followed by treatment with β-estradiol, progesterone (1 μM) and cAMP (1
μM) (EPC), EPC plus prolactin (20 ng/ml), or EPC plus prolactin (20 ng/ml), hPL
(20 ng/ml) and hCG (100 ng/ml) for 4 days. At the end of each experiment,
organoids were removed from Matrigel using Cell Recovery solution and either
stored at −80 °C for later RNA extraction, or processed for western blotting or
immunohistochemistry, as detailed below.
Organoid efficiency formation from single cells. Menstrual and scratch orga-
noids from four patients were grown in the organoid medium for 7 days.
Experiments were performed between passage 2–6, and paired menstrual and
scratch organoids from the same patient were derived at the same growth passage.
After 7 days, organoids were removed from Matrigel using Cell Recovery Solution,
pipetted several hundred times, trypsinized with Trypsin-EDTA for 4 min at 37 °C
and washed in medium to neutralise the Trypsin. Cells were passed through a 40
μm cell strainer (Corning, 352340) to ensure single-cell suspension, and their
numbers counted using a haemocytometer (trypan blue being used to exclude dead
cells). Five-thousand cells were plated per 20 μl Matrigel drop into 48-well plate,
with 5–8-well repeats used per condition. The number of organoids formed after
9 days was scored.
RNA sequencing. RNA was extracted from organoids using RNeasy Plus Universal
Mini Kit (catalogue no. 73404; Qiagen). Libraries were made using the Illumina
TruSeq Stranded mRNA Library Kit according to the manufacturer’s instructions.
Libraries were quantified (kappa qPCR), and equimolar pools were sequenced,
using the Illumina NextSeq500 (1 × 75 bp, 30 Gb, 400M SE/800 M PE reads).
RNA-Seq, 75 bp single end, libraries were generated from matched patient samples
from endometrial scratch (n= 7) and menstrual flow treatment (n= 7). The raw
sequencing data are deposited at EBI-EMBL ArrayExpress with experimental code
E-MTAB-9284.
For each library, original reads files were aligned to GRCh38 human genome
(Ensembl Release 84) with STAR (v2.5.1b_modified)29. Alignments and quality
control (QC) were processed using a ClusterFlow30 (v0.5dev, https://github.com/
ewels/clusterflow) with the ‘fastqc_star’ pipeline. QC reports were assessed using
MultiQC31 (v0.9dev), which includes output from FastQC32 (v0.11.5),
Trim_galore33 (v0.6.4) and fastq_screen34 (version 0.9.3). Gene quantification was
determined with HTSeq-Counts35 (v0.6.1p1). Differential gene expression analysis
was performed with DESeq2 (v1.26.0) package in R36 (v3.6.2). Significant
differentially expressed genes between Menstrual and Endometrial scratch samples
were selected using the threshold for Benjamini–Hochberg (BH) adjusted p-value
< 0.05 and log2Fold-Change greater than 1.
Initial quality control prior to calculating differential expression was by
principal component analysis (PCA). The PCA plot was generated by using the
log2 transformation on the raw count data from DESeq2 with the
rlogTransformation function with option ‘blind=F’. Then the top 2000 most
variables genes were selected to perform the PCA analysis (Fig. 2a). Based on the
PCA plot, the endometrial scratch and the menstrual blood samples did not form
distinct clusters; therefore, a small number of differential expressed genes (DEGs)
were identified. Only 101 genes passed the threshold settings with padj < 0.05 and
absolute log2Fold-Change greater than 1 (equivalent to a 2-fold-change). Figure 2b
shows these 101 DEGs with the log2 transformed counts for each patient sample as
a heatmap, with sample clustering. For each individual patient the endometrial
scratch and menstrual blood are clustered together. Seven sets of marker genes for
menstrual flow organoids are visualised as a heatmap in Fig. 2c using the same log2
transformed counts.
Further details, scripts and expression-count data are available online (https://
github.com/CTR-BFX/Cindrova-Davies_Turco).
Quantitative real-time RT-PCR analysis. Total RNA was isolated from snap-
frozen organoids using RNAeasy kit (Qiagen, Crawley, UK). RNA was quantified
by spectrophotometry (Nanodrop Technologies, DE, USA) and integrity assessed
using an Agilent 2100 bioanalyser (Agilent Technologies UK Limited, UK). In
brief, 20 µg of total RNA from each sample was reverse transcribed using a master
mix containing SuperScript II Reverse Transcriptase in the First Strand Buffer with
0.1 M DTT (Invitrogen, Paisley, UK), 50 ng/ml random hexamers (Sigma). The
DNA Engine Opticon 2 Sequence Detection System (Bio-Rad Laboratories, UK)
was used to perform real-time PCR according to the manufacturer’s protocols
(using TaqMan–FAM1 dye). Ct values for each transcript were compared with
those for 18S rRNA (dCt obtained), and these values were compared to term
control samples (ddCt values are reported). TaqMan gene expression assays
(Applied Biosystems, ABI, Warrington, UK): PAEP (Hs01046125_m1), LIF
(Hs01055668_m1), MUC1 (Hs00159357_m1), 18S (Hs03003631_g1).
Expression levels were calculated applying the comparative Cycle threshold (Ct)
method. Relative expression levels were normalised to the geometric mean of three
housekeeping genes HPRT1 (Hs02800695_m1), TOP1 (Hs002432257_m1) and
TBP (Hs00427620_m1) using Microsoft Office Excel. All qRT-PCR experiments
were carried out with a non-template control.
Western blotting. Organoids were homogenised in ice-cold lysis buffer (1 ml of
buffer per 100 mg tissue) containing 20 mM Tris, pH 7.4, 1 mM EGTA, 0.01 %
Triton x100, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 10 mM
β-glycerol phosphate, 50 mM sodium fluoride and a complete mini protease
inhibitor cocktail (Roche, Roche Diagnostics, East Sussex, UK). Organoid homo-
genates were centrifuged at 15,000 × g, 4 °C for 20 min. Protein concentrations
were determined on the supernatant using a BCA protein assay kit (Sigma, Poole,
UK). Lysates were mixed with 3x SDS PAGE sample buffer, boiled for 5 min and
allowed to return to room temperature. Equal amounts of protein (30 μg) were
separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, using
7.5–12.5% polyacrylamide resolving gels, and transferred onto nitrocellulose
membrane (Invitrogen, Paisley, UK), and subjected to immunoblot analysis.
Membranes were blocked for 1 h at 25 °C in 5% milk diluted in Tris-buffered saline
(TBS) and 0.1% Tween 20 and incubated with anti-glycodelin (Abcam, ab53289,
1:1000), anti-MUC1 (Abcam, ab28081, 1:500), anti-LIF (Santa Cruz, sc-1336,
1:1000), anti-progesterone receptor (Abcam, ab32085, 1:1000) or β-actin (Invi-
trogen, 15G5A11/E2) primary antibodies overnight at 4 °C. After washing and
incubating with secondary antibodies, immunoreactive proteins were visualised by
the ECL plus chemiluminescence system following the manufacturer’s instructions
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(Amersham Biosciences, Bucks., UK). Protein bands were quantified using Image J
software (National Institutes of Health, http://rsb.info.nih.gov/ij/). Protein loading
was normalised against β-actin staining. The values are expressed as a percentage of
the control lysate (100%) for each experiment. All uncropped scans are presented
in Supplementary Figs. 6 and 7.
Glycodelin ELISA assay. At the end of each hormonal treatment experiment,
culture medium was pooled from four wells per condition and centrifuged at
12,000 RPM for 5 min. Supernatants were transferred to a fresh tube and stored at
−80 °C until analysis. Human PP14/glycodelin A ELISA (RayBiotech Inc., ELH-
PP14) was performed using 100 μl supernatant in duplicate alongside a series of
diluted human glycodelin standard according to the manufacturer’s instructions.
The concentration of glycodelin in the supernatants was calculated from the line
formula of the standard plots.
Immunohistochemistry. Organoids were removed from Matrigel using Cell
Recovery Solution, fixed in 4% paraformaldehyde and encapsulated into 1%
agarose (Melford, MB1200), dehydrated and embedded in paraffin wax. 7 μm thick
sections were dewaxed, rehydrated, incubated in 3% H2O2 for 15 min to block
endogenous peroxidase activity. If required, heat-induced antigen retrieval was
performed by boiling sections in Tris-EDTA buffer (10 mM Tris Base, 1 mM
EDTA Solution, 0.05% Tween 20, pH 9.0) in a microwavable pressure cooker for
1–2 min (microwave at 570W). Sections were blocked for 1 h in 5% goat serum, 2%
BSA solution (in TBS) to prevent non-specific antibody binding and incubated
overnight at 4 °C with the appropriate primary antibodies: prolactin receptor
(Preprotech, Cat no: 100-07, no retrieval, 1:500), progesterone receptor (Dako,
M3569, TE, 1:50), acetylated tubulin (Cell Signaling, #611B1, TE, 1:1000), glyco-
delin (Abcam, ab53289, TE, 1:500), Ki67 (Abnova, PAB12127, TE, 1:10,000). This
was followed by detection with avidin-conjugated secondary antibodies, and
visualised with a Vectastain Elite ABC kit (Vector Laboratories, Peterborough, UK)
and SigmaFast DAB (Sigma, Poole, UK). Sections were then lightly counterstained
with haematoxylin, before being dehydrated and mounted.
Quantification of the Ki67 proliferation index. Ki76-stained slides were scanned
using a NanoZoomer (Hamamatsu, Welwyn Garden City, UK). Each slide was
visualised and four random fields of view were captured per slide at x40 magni-
fication. In each image, the number of Ki67-positive nuclei and the total number of
nuclei were counted.
Haematoxylin and eosin (H&E) staining. Seven micrometre thick sections were
dewaxed, rehydrated and stained in Mayer’s haematoxylin for 10 min. They were
then washed in running tap water for 15 min and stained in eosin for 4 min,
followed by dehydration and mounting.
Periodic acid Schiff (PAS) staining. Seven micrometre thick sections were
dewaxed, rehydrated and treated with 1% periodic acid (Sigma, 395132) for 15 min,
rinsed in water, immersed in Schiff’s reagent (Sigma, 3952016) for 15 min, rinsed in
water, counterstained with Mayer’s haematoxylin for 2 min, washed in running tap
water, dehydrated and mounted.
Processing of organoids for semi-thin sections and lectin staining. At the end
of each experiment, organoids (six wells per treatment) were removed from
Matrigel using Cell Recovery Solution, lightly fixed in 1% glutaraldehyde/1% for-
maldehyde for 1 h, washed with human serum, fixed in 2% glutaraldehyde/2%
formaldehyde for 2 h, and washed in cacodylate buffer. The cell pellets were pro-
cessed into epoxy resin, as previously described37. Resin-embedded material was
sectioned at 0.5 µm and stained with 1% toluidine blue in 1% borax on a hotplate in
order to identify suitable areas for lectin staining. Sections were then cut at 0.75 µm,
mounted on APES coated slides and dried at 50 °C for 2 days before staining with
Bandeiraea simplicifolia -II (BSA-II) and Arachis hypogaea agglutinin (AHA)
lectin38. BSA-II lectin binds to amylase-sensitive glycogen, and sections were
treated with 1% amylase for 20 min before staining with BSA-II to detect
glycogen39.
Statistical analysis. Data are expressed as mean ± SD. Comparisons were made
using a two-tailed Student’s t-test or ANOVA with a Tukey’s multiple comparison
post hoc test where appropriate. Differences were considered to be significant at
p ≤ 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All source data underlying the graphs and tables are available in Supplementary Data files
and/or can be found in GitHub with corresponding https://doi.org/10.5281/
zenodo.4696302 (https://zenodo.org/record/4696302#.YHl2RGjTWjg)40. Microcopy
images data are available in Cambridge research repository Apollo with DOI link
(https://doi.org/10.17863/CAM.68319). All other data (if any) are available upon
reasonable request.
Code availability
The customised scripts used for the analysis can be found in the following online
repository: https://github.com/CTR-BFX/Cindrova-Davies_Turco (https://doi.org/
10.5281/zenodo.4696302, https://zenodo.org/record/4696302#.YHl2RGjTWjg)40. The
bioinformatics software used are R version 3.6.2 (corresponding package versions are
listed in GitHub).
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